Application Would Expand Versatility of DelSite cGMP Polymer
IRVING, Texas, Sept. 19 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Pink Sheets: CARN) today announced its wholly-owned subsidiary, DelSite Biotechnologies, Inc., entered into a technology evaluation rights license agreement with a biotechnology company for transdermal delivery of vaccines using GelSite(R) polymer, DelSite's high-molecular-weight anionic polysaccharide which is produced under cGMP with high purity at a kilogram scale. Financial terms of the agreement were not disclosed.
As part of the agreement, DelSite will provide GelSite(R) polymer and assistance in formulation development of a transdermal vaccine. Transdermal vaccination avoids needle sticks, pain or tissue damage and offers distinct advantages over conventional vaccination regimens. The objective of the program is to develop an effective vaccine formulation that may further enhance the immune response following through-the-skin delivery. The GelSite(R) polymer's distinct chemical and functional properties, including its capability for in-situ gel formation that provides a matrix for sustained antigen release, may make it an especially suitable platform for noninvasive transdermal vaccination delivery.
This agreement is a new addition to DelSite's delivery technology programs in the vaccine areas. So far this year, DelSite has entered into five technology rights evaluation agreements with commercial partners in using GelSite(R) polymer for drug or vaccine delivery by various routes. These include intranasal delivery of a Shigellosis vaccine by EndoBiologics, Inc.; intranasal delivery of peptide/protein therapeutics by Nastech Pharmaceutical Company, Inc.; injectable delivery of an HIV peptide vaccine by AriaVax, Inc.; injectable delivery of a cancer therapeutic agent by ElSohly Laboratories; and sublingual delivery of vaccines by the International Vaccine Institute.
Additionally, DelSite initiated work with the National Institutes of Health to evaluate a modification of its GelSite(R) polymer for use as the antigen for a typhoid vaccine, and with the National Cancer Institute for development of needle-free nasal powder delivery of future HPV vaccines.
Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institutes of Health) under the Department of Health and Human Services.
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. More than 130 patents in 26 countries protect Carrington's technology. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.
|SOURCE Carrington Laboratories, Inc.|
Copyright©2007 PR Newswire.
All rights reserved